Literature DB >> 2462263

Radiosensitivity related to neuroendocrine and endodermal differentiation in lung carcinoma lines.

G Duchesne1, A Cassoni, M Pera.   

Abstract

A panel of human lung carcinoma lines was studied with respect to hormone production and intermediate filament expression to distinguish between endodermal and neuroendocrine differentiation. An index of the degree of neuroendocrine differentiation of each line was derived from the presence or absence of hormone production, cytokeratins, neurofilaments and an embryonic endodermal cell marker, which allowed identification of three groups showing high, intermediate or low neuroendocrine expression. This grouping correlated well with the in vitro radiosensitivity of the lines, those expressing pure neuroendocrine features being significantly more radiosensitive than those with an endodermal phenotype, with the intermediate group having intermediate sensitivity. Use of such an index might predict those patients likely to benefit from the use of radiotherapy in their management.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462263     DOI: 10.1016/0167-8140(88)90036-9

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases.

Authors:  Gen-You Yao; Ji-Lin Zhou; Mao-De Lai; Xiao-Qing Chen; Pei-Hui Chen
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Characteristics of two cell lines derived from a histologically undifferentiated bronchial carcinoma expressing neuroendocrine markers.

Authors:  S Wright-Perkins; M R Daniel; C Walker
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-07       Impact factor: 2.416

3.  The Effects of smoking status and smoking history on patients with brain metastases from lung cancer.

Authors:  Rachel F Shenker; Emory R McTyre; Jimmy Ruiz; Kathryn E Weaver; Christina Cramer; Natalie K Alphonse-Sullivan; Michael Farris; William J Petty; Marcelo R Bonomi; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Graham W Warren; Michael D Chan
Journal:  Cancer Med       Date:  2017-04-12       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.